Printer Friendly
The Free Library
5,672,048 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Research and Markets: Increased Need to Maximise Impact of Pharma-patient Group Alliances across Range of Pharma Activities.


DUBLIN, Ireland -- Research and Markets has announced the addition of Harnessing Patient Power: Strategies for speeding drug approval, building and retaining market share to their offering.

Relationships between the pharmaceutical industry and patient groups have changed drastically during the past two decades, they are no longer restricted to financial contributions to create goodwill, with no expectation of a measurable return for the company. This management report outlines the developments in pharma-patient group alliances and provides a guide for maximizing their impact across a range of pharma activities: clinical trial recruitment, product launches, CME CME

See: Chicago Mercantile Exchange


CME

See Chicago Mercantile Exchange (CME).
 programs, disease awareness and education initiatives. Advocacy groups are now more aware of how to leverage their influence, but still seek financial assistance, cutting-edge information about clinical trials, new therapies, professional or technical support, and other in-kind contributions that help them better serve their patient communities. The report uses detailed case studies to pinpoint how pharma companies can convert such relationships into important business tools to meet their corporate objectives.

Topics Covered Include:

--An Introduction to Patient Power

--Case study: Online CML 1. CML - A query language.

["Towards a Knowledge Description Language", A. Borgida et al, in On Knowledge Base Management Systems, J. Mylopoulos et al eds, Springer 1986].
2. CML - Concurrent ML.
 support groups and Novartis' Gleevec

--Case study: Gilead Sciences' Preveon

--Relationships Between Pharma

--Case study: The Terrence Higgins Trust Terrence Higgins Trust is a British charity that campaigns on various issues related to AIDS and HIV. In particular, the charity aims to reduce the spread of HIV and promote good sexual health (including safe sex); to provide services on a national and local level to people with,  (UK)

--Case study: Prostate Cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men.  Awareness Week (US)

--Case study: Coalition of National Cancer Cooperative Groups (US)

--Case study: American Medical Women's Association

--Case study: aging patients

--Case study: American Diabetes Association The American Diabetes Association, or the ADA, is an American health organization providing diabetes research, information and advocacy. Founded in 1940, the American Diabetes Association conducts programs in all 50 states and the District of Columbia, reaching hundreds of  

--Case study: The DoD Breast Cancer Research Project

--Case study: The Breast Cancer Coalition (UK)

--Building Effective Relationships

--Case study: Pharmacia and G.R.O.U.P.

--Case studies: DTCI DTCI Defense Transportation Coordination Initiative
DTCI Digital Trunk Controller ISDN (Telecommunications)
DTCI Digital Trunk Carrier Interface (Hekimian) 
 & DTP See desktop publishing.

DTP - desktop publishing
 

--A Strategic Approach to Forming

--Case study: the Health Coalition Initiative (UK)

--The Future Outlook

For more information visit http://www.researchandmarkets.com/reports/c9321
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 15, 2004
Words:282
Previous Article:Molex Files Fiscal First Quarter Report With SEC; Announces Resignation of Independent Auditors.
Next Article:AGL Resources Announces Equity Offering of 9.6 Million Shares.



Related Articles
SCHWARZ PHARMA ACQUIRES RIGHTS TO DRUG FOR EPILEPSY.(Brief Article)
MGI PHARMA Reports 2002 Third Quarter Results; Palonosetron NDA Submitted On Schedule During Quarter.
MGI PHARMA Reports First Quarter 2003 Financial Results; Company Anticipates Presentation of Pivotal Palonosetron Data At Upcoming Medical Meetings.
MGI PHARMA Reports First Quarter 2004 Financial Results.
MGI PHARMA Reports Second Quarter Financial Results.
MDS Pharma Services Sponsors The Biomarker Alliance'TM'.
MGI PHARMA Provides Corporate Update; 2005 Aloxi(R) Injection Sales Increase 56% To Approximately $248 Million; 2006 Sales of Aloxi(R) Injection...
MGI PHARMA Reports Fourth Quarter and Full Year 2005 Financial Results.
MGI PHARMA Reports First Quarter 2006 Financial Results; First Quarter Highlighted by Execution of Pipeline Initiatives.
The Development of New Drug Pipelines is One of the Challenges Faced by the World's Pharmaceutical Industry.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles